Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest L-DOPA Stories

2014-03-11 23:31:01

Herb Mucuna Pruriens Active Ingredient in Innovative Supplement Beverage Albuquerque, N.M. (PRWEB) March 11, 2014 This March, consumers across the U.S. can “Go Beyond Energy” with Aquadopa, the world’s first herbal supplement beverage to enhance dopamine function. Offering sensations of ambition and drive, Aquadopa gives users an experience not attainable with energy drinks or coffee. Creator Dr. Andrew Hemmen, a board-certified internal medicine physician, believes the drink can...

2014-03-11 08:29:26

REHOVOT, Israel, March 11, 2014 /PRNewswire/ -- NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease....

2014-03-04 16:24:31

Upon completing the survey, Find a Cure Panel will make a donation to a non-profit of your choice LOS ANGELES, March 4, 2014 /PRNewswire/ -- Find a Cure Panel specializes in patient research for serious and rare diseases and conditions, including Parkinson's. They currently have a confidential and anonymous online survey for PD. Both patients and caregivers can qualify. Please read the below and consider participating if you qualify. Survey for patients and caregivers who are on Levodopa...

2014-01-29 12:27:59

NEW YORK, Jan. 29, 2014 /PRNewswire-USNewswire/ -- Research projects from three biopharmaceutical companies in the United States comprise the 2013 second half (2H 2013) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program participants' research projects are presented directly to industry groups who may wish to invest in further development of the project. By connecting industry leaders...

2013-12-19 10:39:56

Deep brain stimulation may have a beneficial effect on driving ability for people with Parkinson's disease, according to a new study published in the December 18, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. Deep brain stimulation uses a surgical implant similar to a pacemaker to send electrical impulses to the brain. "Up until now, we weren't sure how deep brain stimulation would affect driving," said study author Carsten Buhmann, MD, of...

2013-10-22 08:33:22

ALISO VIEJO, Calif., Oct. 22, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient in study AVR-133. The study is a proof of concept, Phase II clinical trial investigating the use of AVP-923 for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease (PD). (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) "This is an important study of a compound with multifaceted...

2013-10-02 12:29:35

Results from the Phase 2/3 EASED Trial Demonstrate an Increase of Approximately Three Hours in ON Time Without Troublesome Dyskinesia for Patients Taking ADS-5102 Compared to Placebo MONTREAL and EMERYVILLE, Calif., Oct. 2, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED((TM)) clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development...

2013-07-11 20:20:56

NEW YORK, July 11, 2013 /PRNewswire-USNewswire/ -- Research projects from five biopharmaceutical companies in the United States, Canada and Israel comprise the 2013 first half (1H 2013) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program participants' research projects are presented directly to industry groups who may wish to invest in further development of the project. By connecting...

2013-06-18 08:30:54

SYDNEY, Australia And EMERYVILLE, Calif., June 18, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102 (amantadine HCl extended release) capsules demonstrating a statistically significant improvement in levodopa-induced dyskinesia (LID) as measured by change from baseline at week 8 versus placebo in the Unified Dyskinesia Rating Scale (UDysRS). ADS-5102 is Adamas' investigational extended-release formulation of amantadine...

2013-06-13 08:28:04

NESS ZIONA, Israel, June 13, 2013 /PRNewswire/ -- NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected for presentation at the 17th International Congress of Parkinson's Disease and Movement Disorders, June 16th-20th in Sydney, Australia. ND0612 is a proprietary levodopa/carbidopa liquid drug formula under...